Loading clinical trials...
Loading clinical trials...
International, Multicenter, Single-arm, Open-label, 12-week Phase IIIb Study to Evaluate RebiSmart™ Suitability for Self Injection of Rebif® New Formulation (RNF) in Multidose Cartridges in Patients With Relapsing Form of Multiple Sclerosis (RMS)
Conditions
Interventions
Rebif® New Formulation (RNF) using RebiSmartTM
Locations
6
United States
US Local Medical Information
Rockland, Massachusetts, United States
Canada, Local Medical Information
Ontario, British Columbia, Quebec, Canada
Germany, Local Medical Information
Hamburg, Ulm, Berlin, Erbach, Germany
Italy, Local Medical Information
Chieti & Roma, Italy, Italy
Spain, Local Medical Information
Barcelona & Madrid, Spain, Spain
Sweden, Local Medical Information
Sweden, Sweden
Start Date
July 1, 2008
Primary Completion Date
January 1, 2009
Last Updated
November 14, 2013
NCT06276634
NCT07225504
NCT06809192
NCT05359653
NCT07376772
NCT07426991
Lead Sponsor
EMD Serono
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions